Vetter to Build US Commercial Facility


Vetter Pharma International will build a 1.2 million-square-foot (112,000-square-meter) commercial injectables manufacturing facility in the US. The company has acquired a 17 acre (7 hectare) site in Des Plaines, Ill., near Chicago’s O’Hare Airport and its clinical manufacturing operation in Skokie. Vetter plans to spend $320 million over a 10-year period to build out the facility, which is expected to employ 300 people initially and up to 500 at full operation. While no state and local incentives were revealed, it is likely that a package of incentives was offered to the company.

Vetter has the largest contract injectables manufacturing revenues in the CM industry, exceeding $500 million with an average annual growth rate of 8.5% over the past five years. Its commercial manufacturing facilities in Ravensburg and nearby Langenargen have capacity to produce nearly 500 million vials, single- and dual-chamber syringes and cartridges.

Vetter’s decision to build a facility in the US is significant for two reasons…

This article is reprinted from the July issue of Bio/pharmaceutical Outsourcing Report. The full article addresses Vetter’s position in the market. To learn more, click here.

Related posts:
Global Bio/pharma Continues to Spend on PP&E
Proposed Saudi Shift Away from Oil May Favor Bio/Pharmaceutical Industry
Watch Out for the Hangover

Jim Miller is the founder and president of PharmSource Information Services, Inc. A preeminent expert in bio/pharmaceutical outsourcing, Jim established and presides over the industry’s principal resource for serious consumers of information on contract drug development and manufacturing, PharmSource STRATEGIC ADVANTAGE. He is editor and publisher of Bio/Pharmaceutical Outsourcing Report and Emerging Markets Outsourcing Report.

More posts by Jim Miller